Shares of Bausch Health Companies Inc. (TSE:BHC – Get Free Report) traded up 8.4% during trading on Thursday following a better than expected earnings announcement. The company traded as high as C$12.37 and last traded at C$12.33. 36,968 shares changed hands during trading, a decline of 90% from the average session volume of 370,617 shares. The stock had previously closed at C$11.37.
The company reported C$1.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C$1.43 by C$0.10. The firm had revenue of C$3.42 billion during the quarter, compared to the consensus estimate of C$3.36 billion. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 2,304.54%.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on BHC shares. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. Raymond James upgraded shares of Bausch Health Companies to a “hold” rating in a research note on Wednesday, July 10th.
Insider Activity at Bausch Health Companies
In related news, Senior Officer Seana Lynne Carson sold 13,370 shares of Bausch Health Companies stock in a transaction on Friday, September 6th. The stock was sold at an average price of C$8.38, for a total transaction of C$112,087.40. 11.28% of the stock is currently owned by corporate insiders.
Bausch Health Companies Stock Up 9.1 %
The company has a market cap of C$4.55 billion, a PE ratio of -7.05, a PEG ratio of 0.21 and a beta of 0.77. The stock’s 50 day moving average price is C$9.82 and its 200-day moving average price is C$9.87. The company has a debt-to-equity ratio of 7,583.76, a quick ratio of 0.58 and a current ratio of 1.19.
Bausch Health Companies Company Profile
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
See Also
- Five stocks we like better than Bausch Health Companies
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Which Wall Street Analysts are the Most Accurate?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
- Why Invest in High-Yield Dividend Stocks?
- Caterpillar Stock: Market Points to a Buying Opportunity
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
